Treatment Chronic UTI Post Kidney Transplant

Shahid Beheshti University of Medical Sciences

Status and phase: Terminated; Phase 3

Conditions: Urinary Tract Infections; Transplant-Related Disorder

Treatments: Biological: Phage

Study type: Interventional

Funder types: Other

Identifiers

NCT05967130

SBMU-

Details and patient eligibility

About

Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering from UTIs with ESBL-E within the first year posttransplant. Moreover, recurrence rates of UTI caused by ESBL-E are almost three times higher than those by cephalosporin-susceptible Enterobacteriums demonstrating the decreased efficacy of antibiotics in the treatment of these UTIs.

Full description

According to each patient's urine culture, resistant urinary tract infections will be treated with specific phages and patients will be followed up with their urine cultures for response to therapy.

Enrollment: 5 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stable Kidney Transplant Recipients
• Stable Immunosupression Dose
• Stable Renal Function
• Resistant Urinary Infection with Positive UC

Exclusion criteria

• Rejection periods
• Frail Patients

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

UC Positives

Experimental group

Description:

Stable Transplanted Patients with Positive UC

Treatment:

Biological: Phage